Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYCand TGF-β-dependent mechanisms

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 31, 2016, Pages E4558-E4566

  Shi, Xiarong ^a   Mihaylova, Valia T ^a   Kuruvilla, Leena ^a   Chen, Fang ^a   Viviano, Stephen ^a   Baldassarre, Massimiliano ^a   Sperandio, David ^b   Martinez, Ruben ^b   Yue, Peng ^b   Bates, Jamie G ^b   Breckenridge, David G ^b   Schlessinger, Joseph ^a   Turk, Benjamin E ^a   Calderwood, David A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BROMODOMAIN INHIBITOR; GS 626510; MESSENGER RNA; MYC PROTEIN; REGULATOR PROTEIN; SHORT HAIRPIN RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRIPARTITE MOTIF CONTAINING PROTEIN 33; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BROMODOMAIN AND EXTRA-TERMINAL DOMAIN PROTEIN, HUMAN; PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRIAZOLE DERIVATIVE; TRIM33 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; CANCER RESISTANCE; CELL PROLIFERATION; COLORECTAL CANCER CELL LINE; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GENE SILENCING; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; COLORECTAL TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

AZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HUMANS; MOLECULAR STRUCTURE; PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRIAZOLES;

EID: 84982731599     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1608319113     Document Type: Article

References (46)

1. Belkina AC, Denis GV (2012) BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 12(7):465-477.
2. Dawson MA, Kouzarides T (2012) Cancer epigenetics: From mechanism to therapy. Cell 150(1):12-27.
3. Filippakopoulos P, Knapp S (2014) Targeting bromodomains: Epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13(5):337-356.
4. Baratta MG, et al. (2015) An in-Tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci USA 112(1):232-237.
5. Zuber J, et al. (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478(7370):524-528.
6. Filippakopoulos P, et al. (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067-1073.
7. Nicodeme E, et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468(7327):1119-1123.
8. Chapuy B, et al. (2013) Discovery and characterization of super-enhancer-Associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24(6):777-790.
9. Da Costa D, et al. (2013) BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J 3:e126.
10. Delmore JE, et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904-917.
11. Herrmann H, et al. (2012) Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-And progenitor cells in acute myeloid leukemia AML. Oncotarget 3(12):1588-1599.
12. Mertz JA, et al. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 108(40):16669-16674.
13. Ott CJ, et al. (2012) BET bromodomain inhibition targets both c-Myc and IL7R in highrisk acute lymphoblastic leukemia. Blood 120(14):2843-2852.
14. Asangani IA, et al. (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510(7504):278-282.
15. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H (2012) Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci USA 109(47):19408-19413.
16. Shi J, et al. (2014) Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 25(2):210-225.
17. Shimamura T, et al. (2013) Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 19(22):6183-6192.
18. Dawson MA, et al. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370):529-533.
19. Bai X, et al. (2010) TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell 142(1):133-143.
20. Dupont S, et al. (2005) Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell 121(1):87-99.
21. Aucagne R, et al. (2011) Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest 121(6):2361-2370.
22. Herquel B, Ouararhni K, Davidson I (2011) The TIF1α-related TRIM cofactors couple chromatin modifications to transcriptional regulation, signaling and tumor suppression. Transcription 2(5):231-236.
23. Vincent DF, et al. (2009) Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet 5(7):e1000575.
24. Dupont S, et al. (2009) FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136(1):123-135.
25. He W, et al. (2006) Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell 125(5):929-941.
26. Sedgwick GG, et al. (2013) Transcriptional intermediary factor 1γ binds to the anaphase-promoting complex/cyclosome and promotes mitosis. Oncogene 32(39): 4622-4633.
27. Kusy S, et al. (2011) Adult hematopoiesis is regulated by TIF1γ, a repressor of TAL1 and PU.1 transcriptional activity. Cell Stem Cell 8(4):412-425.
28. Wang E, et al. (2015) The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer. eLife 4:e06377.
29. Luo B, et al. (2008) Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 105(51):20380-20385.
30. Fraser RA, et al. (1998) The putative cofactor TIF1alpha is a protein kinase that is hyperphosphorylated upon interaction with liganded nuclear receptors. J Biol Chem 273(26):16199-16204.
31. Nielsen AL, et al. (1999) Interaction with members of the heterochromatin protein 1 (HP1) family and histone deacetylation are differentially involved in transcriptional silencing by members of the TIF1 family. EMBO J 18(22):6385-6395.
32. Agricola E, Randall RA, Gaarenstroom T, Dupont S, Hill CS (2011) Recruitment of TIF1γ to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 43(1):85-96.
33. Gregory MA, Hann SR (2000) c-Myc proteolysis by the ubiquitin-proteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20(7):2423-2435.
34. Baker EK, et al. (2015) BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Sci Rep 5:10120.
35. Morsut L, et al. (2010) Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo. Development 137(15):2571-2578.
36. Huang S, et al. (2012) MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 151(5):937-950.
37. Sawyer JS, et al. (2003) Synthesis and activity of new aryl-And heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 46(19):3953-3956.
38. Sawyer JS, et al. (2004) Synthesis and activity of new aryl-And heteroaryl-substituted 5, 6-dihydro-4H-pyrrolo[1, 2-b]pyrazole inhibitors of the transforming growth factorbeta type I receptor kinase domain. Bioorg Med Chem Lett 14(13):3581-3584.
39. Fong CY, et al. (2015) BET inhibitor resistance emerges from leukaemia stem cells. Nature 525(7570):538-542.
40. Marcotte R, et al. (2016) Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164(1-2):293-309.
41. Rathert P, et al. (2015) Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525(7570):543-547.
42. Shu S, et al. (2016) Response and resistance to BET bromodomain inhibitors in triplenegative breast cancer. Nature 529(7586):413-417.
43. Kumar K, et al. (2015) GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep 5:9489.
44. Floyd SR, et al. (2013) The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature 498(7453):246-250.
45. Sun C, et al. (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508(7494):118-122.
46. Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26(1):139-140.